News
12-13-2010, 04:51 AM
Results of the GeparQuinto study, randomized Phase III efficacy data on the use of bevacizumab plus chemotherapy to treat women with early breast cancer will be presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium.
More... (http://www.news-medical.net/news/20101213/GeparQuinto-study-data-on-bevacizumab-plus-chemotherapy-in-early-breast-cancer-to-be-presented-at-33rd-CTRC-AACR.aspx)
More... (http://www.news-medical.net/news/20101213/GeparQuinto-study-data-on-bevacizumab-plus-chemotherapy-in-early-breast-cancer-to-be-presented-at-33rd-CTRC-AACR.aspx)